Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases

Levi, 2002, Cancer mortality in the European Union, 1988–1997, Int. J. Cancer, 98, 636, 10.1002/ijc.10235 Kelly, 1998, Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?, Lung Cancer, 20, 85, 10.1016/S0169-5002(98)00020-8 Sundstrom, 1998, Prognosis of patients treated for intracranial metastases with whole-brain irradiation, Ann. Med., 30, 296, 10.3109/07853899809005858 Nieder, 2000, Prognostic factors in brain metastases, Int. J. Radiat. Oncol. Biol. Phys., 46, 297, 10.1016/S0360-3016(99)00416-2 Postmus, 1999, Chemotherapy for brain metastases of lung cancer, Ann. Oncol., 10, 753, 10.1023/A:1008318515795 Van Vulpen, 2002, Changes in blood-brain barrier permeability induced by radiotherapy, Oncol. Rep., 9, 683 Stupp, 2001, Current and future developments in the use of temozolomide for the treatment of brain tumours, Lancet Oncol., 2, 552, 10.1016/S1470-2045(01)00489-2 Prados, 2001, Temozolomide in combination with other cytotoxic agents, Semin. Oncol., 4, 24, 10.1016/S0093-7754(01)90068-5 Friedman, 1995, Activity of temozolomide in the treatment of central nervous system tumor xenografts, Cancer Res., 55, 2853 Stupp R, Ostermann S, Leyvraz S, et al. Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. PASCO 2001 (abstr. 232). Newlands, 1992, Phase I trial of temozolomide (CCRG 81045: M and B 39831: NSC 362856), Br. J. Cancer, 65, 287, 10.1038/bjc.1992.57 Bower, 1997, Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma, Cancer Chemother. Pharmacol., 40, 484, 10.1007/s002800050691 Bleehen, 1995, Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma, J. Clin. Oncol., 13, 910, 10.1200/JCO.1995.13.4.910 Woll, 1995, Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma, Br. J. Cancer, 72, 183, 10.1038/bjc.1995.299 Britten, 1999, A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies, Clin. Cancer Res., 5, 1629 Dhodapkar, 1997, Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer, Clin. Cancer Res., 3, 1093 Brada, 1999, Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies, Br. J. Cancer, 81, 1022, 10.1038/sj.bjc.6690802 Brock, 1998, Phase I trial of temozolomide using an extended continuous oral schedule, Cancer Res., 58, 4363 Vantongelen, 1994 National Cancer Institute of Canada (NCIC). CTC Expanded Common Toxicity Criteria (http://ctep.info.nih.gov/c3/ctc/htm). Simon, 1989, Optimal two-stage design for phase II clinical trials, Controlled Clin. Trials, 10, 1, 10.1016/0197-2456(89)90015-9 Scagliotti, 2002, Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer, J. Clin. Oncol., 20, 4285, 10.1200/JCO.2002.02.068 Abrey, 2001, A phase II trial of temozolomide for patients with recurrent or progressive brain metastases, J. Neurooncol., 53, 259, 10.1023/A:1012226718323 Christodoulou, 2001, Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases, Ann. Oncol., 12, 249, 10.1023/A:1008354323167 Antonadou, 2002, Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases, J. Clin. Oncol., 20, 3644, 10.1200/JCO.2002.04.140 van Meerbeeck, 2002, A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma, Eur. J. Cancer, 38, 779, 10.1016/S0959-8049(01)00428-2